Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. Tikun Olam-Cannbit Pharmaceuticals Ltd
  6. News
  7. Summary
    TKUN   IL0010843675

TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD

(TKUN)
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Canonic of Evogene Group and Tikun Olam-Cannbit, Sign Production and Distribution Agreements for Canonic Products in Israel

03/25/2021 | 02:00am EST

Canonic Ltd. and Tikun Olam-Cannbit Pharmaceuticals Ltd. announced that they have entered into agreements for the production and distribution in Israel of Canonic's medical cannabis products. Canonic's first product is expected to be launched in Israel next year. According to the production agreement, Tikun Olam Production (Israel) will produce Canonic's medical cannabis products at its factory complying with IMC-GMP standards using Canonic's raw materials, under the Canonic brand. The agreement is not exclusive for either party and consideration paid will be based on the scope of production and related services provided. The agreement is for a period of two years or the production of products from 700kg of raw material, whatever is the earliest. According to the distribution agreement, Tikun Olam Supply and Distribution (Israel) will distribute in Israel Canonic's medical cannabis products, through its distribution channels, on a consignment basis to its or other licensed pharmacies, under the Canonic brand. The initial term of the agreement is 18 months. Consideration to be paid by Canonic will be based on a percentage of sales and for related services.


ę S&P Capital IQ 2021
All news about TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD
08/24Tikun Olam-Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Half Year Ended..
CI
08/19Tikun Olam-Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 12 mill..
CI
08/16Tikun Olam-Cannbit Continues to Expand Its Footprint in the Pharmaceutical Arena
CI
03/30Tikun Olam - Cannbit Pharmaceuticals Ltd Reports Earnings Results for the Full Year End..
CI
03/25Canonic of Evogene Group and Tikun Olam-Cannbit, Sign Production and Distribution Agree..
CI
02/03Tikun Olam-Cannabit and Opiostop LLC Are Establishing A JV to Conduct A Clinical Study ..
CI
01/28Tikun Olam-Cannbit Develops Revolutionary System for the Characterization of Genetic Fi..
CI
2020Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 11.528 million in ..
CI
2019Cannbit Pharmaceuticals Ltd announced that it expects to receive ILS 10.0344 million in..
CI
2019Cannbit Pharmaceuticals Ltd competed the acquisition of Israel activities from Tikun Ol..
CI
More news
Financials
Sales 2020 21,7  6,85  6,85 
Net income 2020 -32,9 M -10,4 M -10,4 M
Net Debt 2020 5,33 M 1,69 M 1,69 M
P/E ratio 2020 -5,03x
Yield 2020 -
Capitalization 133 M 42,0 M 42,0 M
EV / Sales 2019 -
EV / Sales 2020 8 863 230x
Nbr of Employees 100
Free-Float 63,7%
Chart TIKUN OLAM-CANNBIT PHARMACEUTICALS LTD
Duration : Period :
Tikun Olam-Cannbit Pharmaceuticals Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Ifat Kariv Chief Executive Officer & Director
Tony Klein Chief Financial Officer
Eitan Ben-Eliahu Chairman
Ronen Harel Independent External Director
Revital Aviram External Director